Key timeline for Eli Lillys orforglipron: The approval of the first oral GLP-1 pill for weight loss expands the treatment landscape for obesity
Main First identified by Albert Claude in 1945 1 , the endoplasmic reticulum (ER) was later defined by George Palade through electron microscopy as a highly specialized membrane-bound organelle essential for the synthesis, folding, and maturation of secretory and membrane proteins 2
Study Strengths & Limitations Strengths: Large, international, double-blind RCT with adjudicated endpoints Comprehensive, repeated adiposity measures using standardised protocols Sophisticated statistical handling including multiple imputation models for missing data Pre-specified analysis with clear hypotheses Limitations: Predominantly White (77%) and male (63%) cohortgeneralisability to other populations requires confirmation Industry-funded (Novo Nordisk), though with independent academic oversight Post-randomisation analyses of weight/waist changes are observational and cannot prove causation The paradoxical association in placebo between weight loss and increased MACE suggests unintentional weight loss from comorbiditya key confounder The Bottom Line for Clinicians Semaglutide provides robust cardiovascular protection in patients with obesity and established CVD, independent of baseline adiposity and largely independent of weight-loss magnitude
Convenient Capsule Format Easy-to-take capsules fit seamlessly into your daily routine, with no unnecessary fillers
The proportion of patients who achieved the HbA1c goal ranged from 25.9% (95% CI 18.534.9) with alpha -glucosidase inhibitors to 63.2% (54.171.5) with the long-acting GLP-1 analogue
